Floatz Rating
B62/100
Confidence
Indicative
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07234877CT.gov Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets | — | Not Yet Recruiting | — | — | — |
NCT07393555CT.gov Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) | — | Not Yet Recruiting | — | — | — |
NCT07405190CT.gov Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07158489CT.gov Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07630077CT.gov Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities | — | Not Yet Recruiting | — | — | — |
NCT07603791CT.gov Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. | — | Not Yet Recruiting | — | — | — |
NCT07623356CT.gov A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07619339CT.gov A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07412262CT.gov A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression | — | Not Yet Recruiting | — | — | — |
NCT07594522CT.gov A Study of Ivonescimab in People With Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
Show 29 more trialsShow fewer
NCT07590531CT.gov AMT-116 in Combination With Ivosidan in Patients With Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07489703CT.gov SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07535463CT.gov A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07535437CT.gov A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07472478CT.gov Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study) | — | Not Yet Recruiting | — | — | — |
NCT06951646CT.gov ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) | — | Recruiting | — | — | — |
NCT07339839CT.gov Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07397338CT.gov Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | — | Recruiting | — | — | — |
NCT07208773CT.gov A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07204548CT.gov The IVO-LUNG Study | — | Not Yet Recruiting | — | — | — |
NCT07158840CT.gov AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment | — | Not Yet Recruiting | — | — | — |
NCT07086326CT.gov A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06928389CT.gov Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07359040CT.gov Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06936644CT.gov A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation | — | Not Yet Recruiting | — | — | — |
NCT06868732CT.gov Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC | — | Recruiting | — | — | — |
NCT06767514CT.gov Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | — | Recruiting | — | — | — |
NCT06769295CT.gov A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC | — | Recruiting | — | — | — |
NCT06766591CT.gov Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs | — | Not Yet Recruiting | — | — | — |
NCT06684873CT.gov A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN) | — | Not Yet Recruiting | — | — | — |
NCT05899608CT.gov Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | — | Recruiting | — | — | — |
NCT05904379CT.gov AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06396065CT.gov Phase III Study of AK112 for NSCLC Patients | — | Active Not Recruiting | — | — | — |
NCT05636267CT.gov Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients | — | Terminated | — | — | — |
NCT05499390CT.gov AK112 in Advanced Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05247684CT.gov AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC | — | Active Not Recruiting | — | — | — |
NCT05184712CT.gov Phase 3 Clinical Study of AK112 for NSCLC Patients | — | Active Not Recruiting | — | — | — |
NCT04900363CT.gov A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC | — | Completed | — | — | — |
NCT04736823CT.gov A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ivonescimab (this asset) | European Organisation for Research and Treatment of Cancer - EORTC | P3 | B · 62 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Ivonescimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P4 | BB · 66 |
| Metastatic Malignant Neoplasm | — | P2 | BB · 64 |
| Small Cell Lung Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ivonescimab in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ivonescimab-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →